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Under basal conditions, the interaction of the cytosolic protein Keap1 (Kelch-like ECH-
associated protein 1) with the transcription factor nuclear factor-E2-related factor 2 (Nrf2)
results in a low level of expression of cytoprotective genes whose promoter region contains the
antioxidant response element (ARE). Alkylation of one or more of the 27 cysteine sulfhydryl
groups of human Keap1 is proposed to lead to Nrf2 nuclear accumulation, to upregulation of
cytoprotective gene expression by the ARE, and to prevention of degenerative diseases, such
as cancer. Therefore, identification of the most reactive of these cysteine residues toward
specific electrophiles should help clarify this mechanism of cancer prevention, also known as
chemoprevention. To address this issue, preliminary analyses of tryptic digests of Keap1
alkylated by the model electrophile 1-biotinamido-4-(4=-[maleimidoethyl-cyclohexane]-
carboxamido) butane were carried out using liquid chromatographic–tandem mass spectrom-
etry (LC-MS/MS) with a cylindrical ion trap mass spectrometer and also using LC-MS/MS
with a hybrid linear ion trap FT ICR mass spectrometer. Because the FT ICR instrument
provided more complete peptide sequencing coverage and enabled the identification of more
alkylated cysteine residues, only this instrument was used in subsequent studies of Keap1
alkylation by three electrophilic natural products that can upregulate the ARE, xanthohumol,
isoliquiritigenin, and 10-shogaol. Among the various cysteine residues of Keap1, C151 was
most reactive toward these three electrophiles. These in vitro results agree with evidence from
in vivo experiments, and indicate that C151 is the most important site of alkylation on Keap1
by chemoprevention agents that function by activating the ARE through Nrf2. (J Am Soc
Mass Spectrom 2007, 18, 2226–2232) © 2007 American Society for Mass SpectrometryKelch-like ECH-associated protein 1 (Keap1) is acytoplasmic protein that sequesters the tran-scription factor nuclear factor-E2-related factor 2
(Nrf2) in the cytosol under basal conditions [1]. Nrf2 is
a member of the NF-E2 family of nuclear basic leucine
zipper (bZIP) transcription factors. By binding to the
5=-upstream regulatory antioxidant response element
(ARE) regions of cytoprotective genes, Nrf2 upregulates
their transcription [2, 3], thus protecting cells against
damage by reactive oxygen intermediates or other
electrophilic species [4]. Keap1 functions as a bridge
between Nrf2 and the Cullin3-based E3-ligase ubiquiti-
nation complex, promoting ubiquitination and subse-
quent proteasomal degradation of Nrf2 [5–7], thus
preventing nuclear accumulation of Nrf2. Without the
intervention of Keap1, levels of Nrf2 are elevated in the
nucleus causing upregulation of the ARE [8]. Alkylation
of one or more of the 27 cysteine residues of Keap1 by
reactive oxygen species and xenobiotic electrophiles,
including chemopreventive agents, appears to be an
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ARE through Nrf2 [3].
Keap1 has five distinct domains: the N-terminal
domain (amino acids 1–60); the BTB (Bric-a-brac,
Tramtrack, Broad-complex) domain (amino acids 61–
178); a central linker domain (amino acids 179–321); the
Kelch repeat domain (amino acids 322–608); and a
C-terminal domain (amino acids 609–625). The BTB
domain mediates the dimerization of Keap1 [9] and also
binds the adaptor protein in Cul3-dependent ubiquiti-
nation systems [10]. The Kelch repeat domain binds to
the Nrf2 directly [1]. Because Keap1 signaling is prob-
ably mediated by alkylation of one or more of its
cysteine sulfhydryl groups [3, 11, 12], identification of
the cysteine residues that are most reactive toward
specific electrophiles should help clarify this mecha-
nism of action of Keap1.
However, most of the work to date to identify
reactive Keap1 cysteine residues has been carried out
with model alkylating agents such as dexamethasone
21-mesylate [2], iodoacetyl-N-biotinyl hexylene dia-
mine (BIA), and 1-biotinamido-4-(4=-[maleimidoethyl-
cyclohexane]-carboxamido) butane (BMCC) [13] in-
stead of biologically relevant ARE inducers that show
promise as chemopreventive agents. Unlike ARE induc-
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dexamethasone 21-mesylate and BIA is irreversible,
which means that sample preparation would not lead to
dissociation of such adducts. Because BMCC and BIA
are biotinylated compounds, avidin-biotin affinity chro-
matography may be used to facilitate the isolation and
identification of peptides alkylated by these electro-
philes. However, few if any chemoprevention agents
contain biotin tags to facilitate analysis. Therefore, a
general analytical method for the characterization of
alkylated Keap1 must minimize decomposition of ad-
ducts while facilitating the identification of alkylation
sites without the benefit of affinity chromatography.
In this investigation, a method based on liquid
chromatographic–tandem mass spectrometry (LC-MS/
MS) was developed that facilitated the detection of
cysteine residues in human Keap1 modified by chemo-
preventive agents. Because it was anticipated that par-
tial purification of the alkylated peptides from Keap1
might be necessary before LC-MS/MS analysis to detect
all alkylated cysteine residues, preliminary analyses
were carried out of Keap1 that had been alkylated by
the model biotinylated electrophile BMCC using a cy-
lindrical ion trap mass spectrometer (LCQ) or a linear
ion trap-FI ICR mass spectrometer (LTQ-FT ICR). More
BMCC alkylated cysteine residues in human Keap1
could be identified using the LTQ-FT ICR mass spec-
trometer without affinity isolation than when using
either instrument with affinity purification. Therefore,
this method was applied to the analysis of the reaction
products between human Keap1 and each of three
natural products containing Michael acceptors, xantho-
humol, isoliquiritigenin, and 10-shogaol (see structures
in Scheme 1).
Isolated from the hop plant, Humulus lupulus L.
(Cannabaceae), xanthohumol has been reported to be a
cancer chemopreventive agent with activity both in
vitro and in vivo [14 –17]. Isoliquiritigenin is a constit-
uent of the tonka bean Dipteryx odorata (Aubl.) Willd,
and is also present in licorice (Glycyrrhiza uralensis) [18].
Scheme 1. Structures of the natural product ch
xanthohumol [28]; and (C) 10-shogaol [29]. T
compound required to double the intracellular
hepatoma cells [22] and indicate the relative 
reagents.Isoliquiritigenin has been reported to have chemopre-vention activity in both in vitro and several animal
models [19 –22]. 10-Shogaol is a constituent of the
rhizome of Zingiber officinale (ginger) [23]. Although not
attributed specifically to 10-shogaol, ginger has been
reported to have antioxidant and anticarcinogenic
properties by several groups [24 –27]. All three of these
natural products contain electrophilic unsaturated ke-
tones (Scheme 1). As an indication of their chemopre-
ventive activity through the induction of ARE, the
induction of the phase 2 enzyme quinone reductase in
Hepa 1c1c7 murine hepatoma cells by xanthohumol,
isoliquiritigenin, and 10-shogaol has been determined
to be 1.7 0.7, 1.8 0.44, and 42.4 0.9 M, respectively
[22, 28, 29]. In this investigation, the relative reactivities
of each of these compounds toward specific cysteine
residues of human Keap1 were determined using LC-
MS/MS, and the most reactive amino acid residue was
identified as C151 for all three compounds.
Experimental
Materials and Reagents
Recombinant human Keap1 protein containing a histi-
dine tag was expressed in and purified from Escherichia
coli. The details of the cloning, expression, and purifi-
cation of human Keap1 are described elsewhere [30].
BMCC was purchased from Pierce (Rockford, IL), and
trypsin was purchased from Promega (Madison, WI).
An ICAT™ kit for protein labeling was purchased from
Applied Biosystems (Foster City, CA). Deionized water
was prepared using a Milli-Q purification system (Mil-
lipore, Bedford, MA). Acetonitrile (Optima) was pur-
chased from Fisher Scientific (Hanover Park, IL).
Isoliquiritigenin, dimethyl sulfoxide, tris(carboxyleth-
yl)phosphine, D,L-dithiothreitol (DTT), and iodoacet-
amide were purchased from Sigma–Aldrich (St. Louis,
MO, and Milwaukee, WI). 10-Shogaol was isolated and
provided byDr. Yi Tao of the University of Illinois College
prevention agents (A) isoliquiritigenin [22]; (B)
D values represent the concentration of each
one reductase activity in Hepa 1c1c7 murine
ities of these compounds as chemopreventiveemo
he C
quin
activof Pharmacy, and xanthohumol was isolated and pro-
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Sample Preparation
Alkylation of Keap1 by isoliquiritigenin, xanthohumol,
10-shogaol, or BMCC (as a positive control) was carried
out at different ratios as follows (using BMCC as an
example). A stock solution of BMCC was prepared at a
concentration of 10 M in dimethyl sulfoxide. Human
Keap1 (10 M) was incubated with BMCC at molar
ratios from 1:0.025 to 1:2 ([Keap1]/[BMCC]) at room
temperature for 2 h in 100 L 25 mM Tris buffer (pH
8.0). Next, DTT was added to this reaction mixture at a
concentration of 1 mM. After incubation for 30 min,
excess iodoacetamide was added to block the remaining
free cysteines in Keap1. Subsequently, 5 mM DTT was
added to quench unreacted iodoacetamide. Finally, 0.5
g trypsin was added to each Keap1 solution followed
by incubation at 37 °C for 3 h (BMCC) or 1.5 h (all other
electrophiles). The tryptic peptides were analyzed using
LC-MS/MS. Alternatively, BMCC modified peptides
were purified from the tryptic digest of Keap1 using an
avidin affinity column as described by the manufac-
turer of the ICAT kit before analysis by LC-MS/MS.
LC-MS/MS Analyses Using a Cylindrical Ion
Trap Mass Spectrometer
Peptides were analyzed initially using a Finnigan LCQDeca
(Thermo, San Jose, CA) ion trap mass spectrometer
equipped with a Surveyor HPLC system, and a Vydac
(Hesperia, CA, USA) 218MS LC-MS C18 reversed-phase
HPLC column (5 M, 2.1  150 mm, 300 Å) and a 218TP
(5 M, 2.1 mm) guard column. The solvent system con-
sisted of a linear gradient from 5 to 45% solvent B over 60
min and then 45–80% solvent B over 15 min (solvent A:
95:4.9:0.1; and solvent B: 4.9:95:0.1, water/acetonitrile/
formic acid, vol/vol/v) at a flow rate of 200 L/min. The
LCQ mass spectrometer was operated in a data-depen-
dent MS/MS mode in which the most abundant peptide
ion in each mass spectrum was selected for collision-
induced dissociation (CID) using a normalized collision
energy of 35%. The LC-MS/MS data were processed
using Thermo BioWorks™ 3.1 and TurboSEQUEST. The
sites of Keap1 alkylation were identified based on both
automated data processing and manual inspection of the
tandem mass spectra.
LC-MS/MS Analyses Using a Linear Ion Trap-FT
ICR Hybrid Mass Spectrometer
For confirmation of the data obtained using the cylindrical
ion trap, LC-MS/MS analysis of the alkylated Keap1
peptides was also carried out using a high-resolution
Finnigan LTQ-FT ICRmass spectrometer equippedwith a
Dionex (Auburn, CA) microcapillary HPLC system. The
same HPLC separation conditions were used as describedearlier except that a 35-min linear gradient was used from
the 5–45% solvent B. The LTQ-FT ICR mass spectrometer
was operated in a data-dependentMS/MSmode inwhich
the five most abundant peptide ions in each mass spec-
trum were selected for CID using a normalized collision
energy of 35%.
Results and Discussion
Cysteines in Keap1 Modified by BMCC
Because Keap1 has a molecular mass exceeding 70,000
Da, tryptic digestion formed in excess of 100 peptides
(calculated using one missing cleavage site). To detect
all the modified peptides, it was anticipated that partial
purification of the modified peptides would be neces-
sary such as ion-exchange fractionation or affinity ex-
traction before LC-MS/MS analysis. To determine
whether an affinity purification step was necessary, a
preliminary study was carried out using Keap1 that had
been alkylated by the model electrophilic biotinylated
molecule BMCC using a cylindrical ion trap mass
spectrometer (LCQ). As shown in Table 1, avidin puri-
fication usually increased the number of modified pep-
tides detected, though not to a great extent.
Upon acquisition of a linear ion trap FT ICR mass
spectrometer (LTQ-FT ICR MS), the study was updated
using this new instrument for LC-MS/MS analysis. Due
to its faster scan speed and greater sensitivity, more
biotinylated peptides were identified using the LTQ-FT
ICR than the LCQ mass spectrometer, especially when
the ratio of BMCC to protein was low (see Table 1).
Routinely, 90% of the protein sequence was covered by
MS/MS analysis using the LTQ-FT ICR mass spectrom-
eter (compared to only 75 to 80% of sequence coverage
using the LCQ mass spectrometer), and all the cysteine-
containing tryptic peptides were detected. Comparing
the alkylation sites found by using the LCQ and
LTQ-FT mass spectrometers at the same molar ratio of
BMCC and Keap1, more modified sites were detected
using the LTQ-FT mass spectrometer (Table 1). Interest-
ingly, at low ratios, avidin purification actually reduced
the number of detected peptides. This might be due to
the high affinity of the biotin-avidin complex (Kd 
1015 M1) [31], which perhaps retained some of the
biotinylated peptides on the avidin column and caused
some BMCC modified peptides to be lost during the
affinity purification. A more probable possible cause of
the loss of BMCC modified peptides is dissociation of
the BMCC-cysteine adducts during affinity purification.
Given that BMCC is a Michael addition acceptor, it can
modify cysteine residues reversibly. Therefore, during
avidin-biotin affinity purification, some of the adducts
probably dissociated before they could be detected.
FT ICR mass spectrometry greatly facilitated the iden-
tification of alkylated cysteine residues in human Keap1,
in particular, those that could not be purified by affinity
means. Therefore, this FT ICR mass spectrometer-based
method was used without affinity column purification in
whi
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ities of Keap1 cysteines toward ARE inducers.
Modification Sites of Human Keap1
by Electrophiles
Because FT ICR LC-MS/MS facilitated the identification
of sites of cysteine alkylation by electrophiles in human
Keap1 without the requirement of affinity column en-
richment of alkylated peptides, this instrument was
used for the detection of the alkylation sites in Keap1
after reaction with electrophiles lacking affinity tags
such as biotin. Specifically, this method was used to
determine the modification pattern of Keap1 after
alkylation by ARE inducers containing a Michael addi-
tion moiety. Three different electrophilic natural prod-
ucts—isoliquiritigenin, xanthohumol, and 10-shogaol
(Scheme 1)—were incubated with Keap1. Incubations
with a range of concentrations of these electrophiles
were used to determine through a titration-like process
which Keap1 cysteine residues became alkylated first.
Trypsin digestion followed by peptide mapping and
sequencing of the alkylated Keap1 protein were carried
out to determine the sites of alkylation. As expected,
only cysteine residues were alkylated, and these resi-
dues are shown in Table 2. The three most readily
modified cysteines of human Keap1 by xanthohumol
were identified as C151, C319, and C613. The two most
readily modified cysteines of human Keap1 by
isoliquiritigenin were identified as C151 and C226. The
three most readily modified cysteines of human Keap1
by 10-shogaol were C151, C257, and C368. The tandem
Table 1. Alkylation of cysteine residues in human Kelch-like EC
[maleimidoethyl-cyclohexane]-carboxamido) butane (BMCC) as a
[BMCC]/[Keap1]
Avidin
purification
Modified cysteines detected u
ion trap MS
0.025 No Noneb
0.025 Yes None
0.05 No None
0.05 Yes None
0.1 No None
0.1 Yes None
0.5 No C151
0.5 Yes None
1 No C151, C319, C273, C257, C297
1 Yes C151, C319, C273, C257, C297
2 No C151, C319, C273, C257, C297
2 Yes C151, C319, C273, C257, C297
C622, C288, C241, C23
aBMCC was incubated with Keap1 at different molar ratios, and at
instruments: a cylindrical ion trap mass spectrometer and a linear ion
b“None” indicates that no peptides containing BMCC modified cystein
cPeptides detected containing BMCC modified cysteine. The order in
abundances.mass spectra of the peptide ions containing C151 resi-dues that had been alkylated by xanthohumol,
isoliquiritigenin, or 10-shogaol are shown in Figure 1.
Before the discovery of Keap1 protein, Talalay et al.
[32] had proposed that there must be a protein with
highly reactive cysteine thiols that acts as a sensor for
phase 2 inducers. Since the isolation of Keap1 from a
yeast system using a Gal4-Neh2 fusion protein [33],
great interest has focused on the reactivity of Keap1
cysteine residues. Dinkova-Kostova et al. [2] studied the
reaction of murine Keap1 with dexamethasone mes-
ylate using mass spectrometry and suggested that C257,
C273, C288, and C297 were the most reactive sites
among the 25 murine Keap1 cysteine residues. In their
studies of murine Keap1, Dinkova-Kostova et al. [2]
used MALDI-TOF to identify modified peptides in a
tryptic digest, but LC-MS/MS was used to confirm the
sequence and to determine the site of modification in
only two of the four modified peptides. Our previous
study [30] in which human Keap1 modifications were
mapped indicated that C151, C288, and C297 are the
most reactive residues toward iodoacetyl-N-biotinyl
hexylene diamine. A similar study was reported by
Hong et al. [13], but their data suggested that C169,
C241, and C288 but not C151 were reactive toward
human Keap1. Subsequently, we found that a limitation
of the sample preparation procedure used by Hong et
al. [13] had resulted in their inability to detect the
modified C151 peptide [36]. Specifically, Hong et al.
[13] used an ultracentrifugation device for buffer ex-
change, which resulted in the binding and loss of 99%
of the protein due to adsorption and possibly changed
the conformation of Keap1 so that a different modifica-
sociated protein 1 (Keap1) by 1-biotinamido-4-(4=-
tion of BMCC concentrationa
the cylindrical Modified cysteines detected using the linear
ion trap-FT ICR MS
C151, C434c
None
C151, C434
None
C151, C434, C288, C319, C613
None
C151, C434, C288, C319, C613, C226, C257,
C297
C434, C288, C319, C297.
C151, C434, C288, C319, C613, C226, C257,
C297, C77, C273
3, C226 C151, C434, C288, C319, C613, C226, C257,
C297, C77, C273
3, C226, C434 C151, C434, C288, C319, C613, C226, C257,
C297, C77, C273, C23, C38
3, C226, C434, C151, C434, C288, C319, C613, C226, C257,
C297, C77, C273, C23, C38
molar ratio, the tryptic peptides of Keap1 were analyzed using two
T ICR mass spectrometer.
idues were detected.
ch these modified cysteines are listed corresponds to their relativeH-as
func
sing
, C61
, C61
, C61
each
trap-F
e restion pattern was detected [36].
al exp
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acterize the reactivity of human Keap1 toward Michael
addition reaction acceptors from natural products that
upregulate the ARE. Furthermore, this approach facili-
tated the identification of the most reactive amino acid
residues in Keap1. Although the Keap1 alkylation pat-
tern was unique for each electrophile, only cysteine
residues were alkylated, and C151 was always detected
among the top three most reactive cysteines. At a ratio
of electrophile to Keap1 of only 2:1, which was the
smallest ratio tested, 10-shogal and isoliquiritigen but
not xanthohumol alkylated C151 to a detectable level.
As the ratio of electrophile to Keap1 in the incubation
was increased, cysteine modifications by isoliquiritigen
and 10-shogal were detected on all five protein do-
mains. Xanthohumol was the least reactive of the three
electrophiles; no modification sites were detected at a
ratio of 2 to 1, but at a ratio 5 to 1, C151 (located in BTB
domain), and C319 (located in central linker domain)
and C613 (located in Kelch repeat domain) were
modified.
The differences among adduct patterns of these three
electrophiles may be due to their unique structures and
reactivities. Regardless, these results indicate C151 is
extremely reactive toward these three chemoprevention
agents. Located in the BTB domain of Keap1, site-
Table 2. Cysteine residues in Keap1 modified by chemoprevent
Domain Cysteine
[Xanthohumol]/[Keap1]
5 10 20
N-terminal C13
C14
C23
C38 1,2
BTB C77 3 3
C151 1,2,3 1,2,3 1,2,3
C171
Central linker C196
C226
C241
C249
C257
C273
C288
C297
C319 1,2,3 1,2,3 1,2
Kelch C368
C395
C406
C434 1,2 1,2,3
C489 1,2,3
C513 3
C518
C583
C-terminal C613 1,2,3 1,2,3 1,2,3
C622
C624
These data represent the results of LC-MS/MS analyses of three identic
in which specific modified cysteines were detected.directed mutagenesis studies have indicated that C151is essential for inhibition of Keap1-dependant ubiquiti-
nation and degradation of Nrf2 in response to all tested
agents, including tBHQ and sulforaphane [3], NEPP11,
an endogenous neurite outgrowth-promoting prosta-
glandin [34], and ebselen, a seleno-organic drug [35].
Taken together, C151 plays a critical role in the Keap1-
Nrf2 signaling system, and our results support the view
that C151 is a target for Nrf2 activation by Michael
addition reaction acceptors that function as ARE
inducers.
Conclusions
The use of FT ICR LC-MS/MS facilitated the identifica-
tion of sites of cysteine alkylation by electrophiles in
human Keap1 digested with trypsin without the need
for affinity column enrichment of alkylated peptides.
The reaction of Keap1 with the Michael addition reac-
tion acceptors xanthohumol, isoliquiritigenin, and 10-
shogaol, which are natural products that upregulate the
ARE, was investigated using this method. All three
compounds alkylated Keap1 at specific cysteine resi-
dues, and the most reactive site of Keap1 was C151. This
information suggests that natural product chemopre-
vention agents that are Michael addition reaction accep-
tors upregulate the ARE as a result of alkylation of
gents as indicated by LC-MS/MS analysis
[Isoliquiritigenin]/[Keap1] [10-Shogaol]/[Keap1]
2 5 10 2 5 10
1,2
1,2
1,2 1,2,3 2,3
1 2,3
1,2,3 1,2,3
1,2,3 1,2,3 1,2,3 1,2,3 1,2,3 1,2,3
1,2 1,2,3
1,2 1,2,3 1,2,3 1,2,3
1,2,3 1,2,3
1 1,2,3 1,2,3
1,2,3 1,2,3 1,2,3
1,3
3 1,2,3 1,2,3 1,2,3 1,2,3
1,3 1,2,3 1,2,3 1,2,3
1,2 1,2,3
1,3 1,2,3 1,2,3
2 1,2,3 1,2,3
1,2 1,2,3
1,2 1,2,3
2 1,2,3 1,2,3
3 1,2,3 1,2,3 1,2,3
1,2,3 1,2,3
1,2,3 1,2,3
eriments. The numbers indicate the experiment numbers (1, 2, and 3)ive aKeap1 at C151.
ificat
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